title: Doxorubicin and cisplatin chemotherapy in high-grade spindle cell sarcomas of the bone, other than osteosarcoma or malignant fibrous histiocytoma: a European Osteosarcoma Intergroup Study.
abstract: There are limited data that define the role of chemotherapy in the treatment of high-grade spindle cell sarcomas of bone, other than osteosarcoma or malignant fibrous histiocytoma (MFH-B). This prospective study evaluates the effect of doxorubicin and cisplatin on these tumours. Thirty-seven patients, age 65 years, with spindle cell sarcoma of bone, except osteosarcoma or MFH-B, were included. Chemotherapy consisted of doxorubicin and cisplatin every 3 weeks for six cycles. Resection was performed after three cycles. In 15 patients with metastases, response assessment showed three complete responses (CR), four stable disease (SD), five progression; three were not evaluable. Median time to progression was 30 months (95% Confidence Interval (CI), 8-51 months) for the operable non-metastatic patients; median survival 41 months (95% CI, 16-82 months). Median time to progression in the metastatic group was 10 months (95% CI, 0-18 months) and median survival was 14 months (95% CI, 4-45 months). This study suggests a limited role for doxorubicin and cisplatin in metastatic high-grade spindle cell sarcoma of bone, other than osteosarcoma or MFH-B cases.
authors.affiliation: Department of Clinical Oncology K1-P, Leiden University Medical Centre, P.O. Box 9600, 2300 RC Leiden, The Netherlands. M.A.Nooji@lumc.nl
authors.forename: M A
authors.initials: MA
authors.lastname: Nooij
authors.forename: J
authors.initials: J
authors.lastname: Whelan
authors.forename: V H C
authors.initials: VH
authors.lastname: Bramwell
authors.forename: A T
authors.initials: AT
authors.lastname: Taminiau
authors.forename: S
authors.initials: S
authors.lastname: Cannon
authors.forename: P C W
authors.initials: PC
authors.lastname: Hogendoorn
authors.forename: J
authors.initials: J
authors.lastname: Pringle
authors.forename: B M
authors.initials: BM
authors.lastname: Uscinska
authors.forename: S
authors.initials: S
authors.lastname: Weeden
authors.forename: A
authors.initials: A
authors.lastname: Kirkpatrick
authors.forename: M v
authors.initials: Mv
authors.lastname: Glabbeke
authors.forename: A W
authors.initials: AW
authors.lastname: Craft
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D003131:Combined Modality Therapy; D018450:Disease Progression; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D035583:Rare Diseases / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D012509:Sarcoma / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D004317:Doxorubicin; D002945:Cisplatin